Wire · AZ Weekly PostCSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis
Oct 5 (Reuters) - Australia's CSL said on Monday it had entered into an agreement with Switzerland-based Alentis Therapeutics to co-develop and co-promote a treatmen…